Paul J. Shami, M.D.

Locations

Bio

Dr. Paul Shami is a Professor of Medicine in the Division of Hematology and Hematologic Malignancies at the University of Utah and is a Member and Clinical Investigator at the University’s Huntsman Cancer Institute (HCI) . Dr. Shami also holds an Adjunct appointment as a Professor of Pharaceutics and Pharmaceutical Chemistry at the University of Utah. He is Board Certified in Internal Medicine, Hematology and Medical Oncology. Dr. Shami oversees the leukemia program at Hunstman Cancer Institute, where he has established the most comprehensive leukemia clinical trials program in the Intermountain West. Because of his expertise and national recognition in the treatment of blood cancers, he sits on the Acute Myeloid Leukemia, Chronic Myelogenous Leukemia and Myelodysplastic Syndrome panels of the National Cancer Center Network (NCCN). These NCCN panels develop guidelines that are followed nationally and internationally for the treatment of cancer.

For questions regarding Dr. Shami's practice, our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist/New Patient Coordinator at http://www.huntsmancancer.org or (801) 585-6906.

Board Certification and Academic Information

Board Certification and Academic Information

Academic Office Locations

Academic Bio

Paul J. Shami, M.D. is a Professor of Medicine in the Division of Hematology and Hematologic Malignancies, Department of Internal Medicine at the University of Utah. He is an Investigator at Huntsman Cancer Institute, a member of the Experimental Therapeutics program, and holds an adjunct appointment of Professor in the Department of Pharmaceutics and Pharmaceutical Chemistry.

Dr. Shami oversees the leukemia program at Hunstman Cancer Institute, where he has established the most comprehensive leukemia clinical trials program in the Intermountain West. Because of his expertise and national recognition in the treatment of blood cancers, he sits on the Acute Myeloid Leukemia, Chronic Myelogenous Leukemia and Myelodysplastic Syndrome panels of the National Cancer Center Network (NCCN). These NCCN panels develop guidelines that are followed nationally and internationally for the treatment of cancer.

He initially established his research lab at the George E. Wahlen Veterans Affairs Medical Center, where he was Chief of Hematology/Oncology between 2002 and 2005. In 2004 his lab was moved to the University of Utah. The Shami laboratory focuses on the development of new therapies for cancer. In collaboration with a team of chemists (led by Dr. Larry Keefer) at the National Cancer Institute, he has developed a new class of drugs that deliver nitric oxide to cancer cells in a targeted fashion. To lead this effort, he founded JSK Therapeutics Inc. (JSKT), a Utah-based biotech start-up company. Dr. Shami has received multiple grants and significant support from the Leukemia and Lymphoma Society, and the National Cancer Institute.

Dr, Shami obtained his B.S. in Chemistry at the American University of Beirut in Lebanon, followed by his degree in medicine at the same institution. He completed both his internship and residency in Internal Medicine at Duke University in Durham, North Carolina. He remained at Duke to accomplish two Fellowships: One in Hematology/Oncology and the other, a Research Fellowship, in Cell Biology.

Education History

Selected Provider Publications